Envista Holdings Corporation (NVST)
NYSE: NVSTHealth CareMedical/Dental InstrumentsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
NVST stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.70B
- P/E (TTM)
- 39.72
- Forward P/E
- 13.85
- EPS (TTM)
- $0.58
- Dividend yield
- None
- 52-week range
- 18.77 – 30.42
- Day range
- 22.90 – 23.47
- Volume / Avg
- 1.83M / 2.84M
- Beta
- —
- Shares outstanding
- 160.62M
- Next earnings
- Nov 4, 2026
52-week range
NVST stock today
Envista (NVST) closed at $23.04 on Oct 7, down 0.99% (-$0.23), versus the S&P 500's 0.22% decline. Shares are 24.3% below their 52-week high of $30.42, set on Feb 11, 2026 and 22.7% above the 52-week low of $18.77, in the middle of the past year's range. NVST is up 6.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 12.8%.
At 39.7x trailing earnings, Envista trades below the peer-group median of 49.1x. Its forward P/E of 13.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Envista's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Envista
Company profileEnvista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Paul A. Keel
- Headquarters
- Brea, CA
- Employees
- 12,000
- IPO year
- 2019
- Website
- envistaco.com
Analyst forecast
ForecastConsensus (15 analysts)
buy
Avg. price target
$29.69+28.86%
- Strong buy 2
- Buy 6
- Hold 7
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $0.35
NVST news
All NVST newsEnvista peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ICUIICU Medical Inc. | 156.03 | -2.32% | $3.90B | vs NVST |
| PLSEPulse Biosciences Inc | 49.09 | -1.33% | $3.50B | vs NVST |
| IRTCiRhythm Holdings Inc. | 104.99 | -2.06% | $3.46B | vs NVST |
| HTFLHeartflow Inc. | 49.36 | -2.62% | $4.29B | vs NVST |
| HAEHaemonetics Corporation | 101.71 | -1.75% | $4.63B | vs NVST |
| ATRCAtriCure Inc. | 53.31 | -0.69% | $2.71B | vs NVST |
| MMSIMerit Medical Systems Inc. | 85.09 | +0.15% | $5.08B | vs NVST |
| UFPTUFP Technologies Inc. | 292.87 | -3.30% | $2.27B | vs NVST |
Indexes, lists and sector
Envista stock FAQ
What is Envista's stock price today?
NVST last traded at $23.04 as of Oct 7, 4:00 PM EDT, down 0.99% on the day. Prices are delayed at least 15 minutes.
When is Envista's next earnings date?
Envista is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $0.35.
What is NVST's P/E ratio?
NVST trades at a trailing P/E ratio of 39.72 and a forward P/E of 13.85, compared with a median of 49.1 for its closest peers.
Who is Envista's CEO?
Mr. Paul A. Keel is the chief executive officer of Envista Holdings Corporation, which has about 12,000 employees.
What is the NVST 52-week high?
The 52-week high for NVST is $30.42 and the 52-week low is $18.77. The stock is currently 24.3% below its high.